Liang, Lei
Li, Chao
Wang, Ming-Da
Wang, Hong
Zhou, Ya-Hao
Zeng, Yong-Yi
Zhang, Wan-Guang
Chen, Ting-Hao
Wang, Nan-Ya
Li, Jie
Zhang, Yao-Ming
Wang, Yu
Gu, Wei-Min
Xing, Hao
Diao, Yong-Kang
Lau, Wan Yee
Zhang, Cheng-Wu
Pawlik, Timothy M.
Shen, Feng
Huang, Dong-Sheng
Yang, Tian
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81472284, 81672699)
Article History
Received: 19 September 2021
Accepted: 27 September 2021
First Online: 12 October 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of all participating hospitals.
: The study protocol was approved by the Institutional Review Board of all participating hospitals, and informed consent from the patients was waived. Written, informed consent for the data to be used for clinical researches was obtained from all enrolled patients.
: The abstract of this study has been presented as an oral presentation in the Congress of “the 11th Asia-Pacific Primary Liver Cancer Expert, APPLE 2021” (August 13–15, 2021, Korea), and has been also presented as an oral presentation in the Congress of “the LIVER WEEK 2021” (May 13–15, 2021, Korea) and won a “Foreign Investigator Award”.
: All authors declare that they have no conflict of interest.